- Home
- BNC vs NMRA Comparison
BNC vs NMRA Comparison
Compare BNC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNC | NMRA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 311.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | BNC | NMRA |
|---|---|---|
| Price | $2.94 | $1.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 508.7K | ★ 3.6M |
| Earning Date | 07-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.83 |
| 52 Week High | $31.62 | $3.65 |
Technical Indicators
Market Signals| Indicator | BNC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 48.68 |
| Support Level | $2.62 | $1.50 |
| Resistance Level | $3.23 | $2.00 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 61.02 | 25.42 |
Price Performance
Historical ComparisonAbout BNC CEA Industries Inc.
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.